From: The role of exosomes in lung cancer metastasis and clinical applications: an updated review
Experimental model/source | Exosomal component | Predictive effect | References |
---|---|---|---|
Mouse syngeneic tumor model | miR-210-3p, miR-193a-3p, and miR-5100 | miR-193a-3p alone can differentiate cancer patients from non-cancerous controls, but the combination of the three gives better diagnostic accuracy | [86] |
Primary SCLC tissues and NSCLC tissues | FLI1 exonic circular RNAs | Serum exosomal FECR1 is associated with poor survival and clinical response to chemotherapy | [104] |
Human NSCLC tissue | miR‐18a, miR‐20a, miR‐92a, miR‐210, and miR‐126 | Prognostic biomarkers in patients with NSCLC—poor prognosis | [109] |
NSCLC patients | eIF4E | Independent prognostic factor for shorter overall survival and progression-free survival | [111] |
Lung cancer patients’ serum | miR-574-5p, 328-3p and miR-423-3p | Deferential in lung cancer patients with bone metastasis | [78] |
NSCLC patients | miR-330-3p | Biomarker for identifying NSCLC with metastatic potential, especially brain metastasis | [80] |
Serum of NSCLC patients and lung squamous cell carcinoma of patients | miR-15a-5p, miR-320a, miR-25-3p, miR-192-5p, let-7d-5p, let-7e-5p, miR-148a-3p, miR-92a-3p, miR-375 and miR-10b-5p | Deferential in lung cancer patients and correlates with cancer stage | [99] |
NSCLC cells | miR-34c-3p | Diagnostic and prognostic marker for NSCLC with low levels indicating tumor invasion and migration | [116] |
Serum of lung cancer patients | miR-106b | Promising diagnostic biomarker and drug target for patients with lung cancer | [100] |
Serum of lung cancer patients | CD317 and EGFR | Diagnostic biomarker of NSCLC | [101] |
Urine and lung tissue of NSCLC patients | LRG1 | Diagnostic biomarker of NSCLC | [102] |
Plasma of lung cancer patients | CD151, CD171, and tetraspanin 8 | Diagnostic biomarker of lung cancer | [103] |